Programme

 
Home
 
Overview
 
Programme/Posters
 
Speakers/Abstracts
 
Presentations
 
Sponsors
 
Symposium Pictures
 
Symposium Report
 
Kinase Links
 
Meetings
 
Speakers Articles
 
 
 
Programme as of 15th November 2006
Download the programme
Download the posters abstract
SUNDAY, 3RD DECEMBER 2006:
  • 14.00 - 19.00:
  •   Registration / Poster setup and poster session
  • 18.00 - 20.00:
  •   Reception and Opening Apero
     
    MONDAY, 4TH DECEMBER 2006:
  • Session I
  •   Chair: Dr. Brian A. Hemmings, Friedrich Miescher Institute for Biomedical Research, Basel
  • 08.30 - 09.00:
  •   Opening Ceremony
  • 09.00 - 09.40:
  •   Prof. Tony Hunter, The Salk Institute, La Jolla, CA, USA
    The history of the kinome and its use to develop inhibitors
  • 09.40 - 10.20:
  •   Prof. Tony Pawson, Samuel Lunenfeld Research Institute, Toronto, ON, Canada
    Kinome signalling through regulated protein-protein interactions in normal and cancer cells
  • 10.20 - 10.50:
  •   Coffee
  • Session II
  •   Chair: Prof. Paul Herrling, Head Corporate Research, Novartis International, Basel, Switzerland
  • 10.50 - 11.30:
  •   Prof. Axel Ullrich, Max-Planck-Institute for Biochemistry, Martinsried, Germany
    Mining the oncokinome 20 years plus: per aspera ad astra of cancer therapy
  • 11.30 - 12.10:
  •   Prof. Joseph Schlessinger, Yale University School of Medicine, New Haven, CT, USA
    Cell signaling by receptor tyrosine kinases: from bench to bedside
  • 12.10 - 12.50:
  •   Prof. Nancy E. Hynes, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Targeting the ErbB receptors in cancer
  • 13.00 - 14.30:
  •   Lunch
  • Session III
  •   Chair: Dr. Elisabeth Buchdunger, Novartis Institutes for BioMedical Research, Basel, Switzerland
  • 14.30 - 15.10:
  •   Dr. Kari Alitalo, University of Helsinki, Helsinki, Finland
    VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
  • 15.10 - 15.50:
  •   Prof. Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden
    Signalling via receptors for PDGF and TGF-beta - possible targets for tumor therapy
  • 15.50 - 16.30:
  •   Prof. Sir Philip Cohen, MRC, University of Dundee, Scotland, UK
    Targeting protein kinases for the development of anti-inflammatory drugs
  • 16.30 - 17.00:
  •   Coffee
  • Session IV
  •   Chair: Prof. Bernd Groner, Georg Speyer House, Institute for Biomedical Research, Frankfurt am Main, Germany
  • 17.00 - 17.40:
  •   Dr. Nick Lydon, Granite Biopharma LLC, Wilson, WY, USA
    From Gleevec to targeting the kinome
  • 17.40 - 18.20:
  •   Dr. Paul Manley, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Nilotinib: A new Bcr-Abl kinase inhibitor for the treatment of imatinib-resistant CML and GIST
  • 18.20 - 19.00:
  •   Prof. Alex Matter, Novartis Institute for Tropical Diseases (NITD), Singapore, Singapore
    Kinases as drug targets in infectious diseases
  • 19.00 - 21.00:
  •   Poster session
     
    TUESDAY, 5TH DECEMBER 2006:
  • Session V
  •   Chair: Christoph Moroni, Department Clinical-Biological Sciences, University of Basel, Basel, Switzerland
  • 08.30 - 09.10:
  •   Prof. George Demetri, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Treating the kinase signalling addiction in solid tumors: lessons learned from GIST as a paradigm of molecularly targeted therapy
  • 09.10 - 09.50:
  •   Prof. Alexander Levitzki, The Hebrew University of Jerusalem, Israel
    Targeting the EGFR and the PKB pathway
  • 09.50 - 10.30:
  •   Prof. Sara A. Courtneidge, The Burnham Institute, La Jolla, CA, USA
    The involvement of Src and its substrates in cancer cell invasion
  • 10.30 - 11.00:
  •   Coffee
  • Session VI
  •   Chair: Prof. Max M. Burger, Chairman Novartis Science Board, Novartis International, Basel, Switzerland
  • 11.00 - 11.40:
  •   Prof. Owen Witte, University of California, Los Angeles, CA, USA
    Modeling prostate cancer progression and therapy by tissue regeneration
  • 11.40 - 12.20:
  •   Prof. James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
  • 12.20 - 13.00:
  •   Prof. David Livingston, Dana-Farber Cancer Institute, Boston, MA, USA
    Kinase shRNA screening in fresh, primary human ovarian cancer cells
  • 13.00 - 14.30:
  •   Lunch
  • Session VII
  •   Chair: Prof. Georges-A. Hollaender, Department Clinical-Biological Sciences, University of Basel, Basel, Switzerland
  • 14.30 - 15.10:
  •   Prof. Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain
    CDKs and the cell cycle
  • 15.10 - 15.50:
  •   Prof. Adrian Merlo, University Hospital, Basel, Switzerland
    Translating biology into clinics: the case of glioblastoma
  • 15.50 - 16.30:
  •   Prof. Radek Skoda, Department Clinical-Biological Sciences, University of Basel, Switzerland
    Mutated JAK2 and myeloproliferative disorders
  • 16.30 - 17.00:
  •   Coffee
  • Session VIII
  •   Chair: Prof. Ruth Chiquet, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland
  • 17.00 - 17.40:
  •   Prof. Bill Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
    Linking somatic genetics alterations in cancer to therapeutics
  • 17.40 - 18.20:
  •   Prof. Michael Stratton, Wellcome Trust Sanger Institute, Hinxton, UK
    Screen of the full protein kinase gene family for somatic mutations
  • 18.20 - 19.00:
  •   Prof. Victor Velculescu, John Hopkins University School of Medicine, Baltimore, MD, USA
    Genomic analysis of human cancer
  • 19.00 - 21.00:
  •   Poster session
     
    WEDNESDAY, 6TH DECEMBER 2006:
  • Session IX
  •   Chair: Dr. Juerg Zimmermann, Novartis Institutes for BioMedical Research, Basel, Switzerland
  • 08.30 - 09.10:
  •   Dr. Carlos Garcia-Echeverria, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Blocking the IGF-IR/PI3K survival signalling pathway in cancer cells
  • 09.10 - 09.50:
  •   Prof. Thomas M. Roberts, Dana-Farber Cancer Institute, Boston, MA, USA
    Targeting PI3 kinase in cancer
  • 09.50 - 10.30:
  •   Prof. David Barford, Institute of Cancer Research, London, UK
    Structural basis for activation of B-RAF by oncogenic mutations and PKB/Akt by phosphorylation
  • 10.30 - 11.00:
  •   Coffee
  • Session X
  •   Chair: Prof. Matthias Wymann, Department Clinical-Biological Sciences, University of Basel, Switzerland
  • 11.00 - 11.40:
  •   Prof. Mike Hall, Biozentrum, University of Basel, Basel, Switzerland
    TOR signalling and control of cell growth
  • 11.40 - 12.20:
  •   Prof. George Thomas, Genome Research Institute, University of Cincinnati Medical School, Cincinnati, OH, USA
    Targeting TSC with RAD001: The TSC1/2 tumor suppressor and proto-oncogene Rheb in mTOR signalling
  • 12.20 - 13.00:
  •   Dr. Heidi Lane, Novartis Institutes for BioMedical Research, Basel, Switzerland
    A review of the potential of mTOR inhibitors for the treatment of human cancer
  • 13.00 - 14.00:
  •   Lunch
  • Session XI
  •   Chair: Dr. Jan Hofsteenge, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland
  • 14.00 - 14.40:
  •   Prof. Michael B. Yaffe, Massachusetts Institute of Technology, Cambridge, MA, USA
    A novel cell cycle checkpoint kinase pathway that integrates global stress response's and DNA damage
  • 14.40 - 15.20:
  •   Prof. Susan M. Gasser, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland
    ATR kinases at sites of DNA damage
  • 15.20 - 16.00:
  •   Prof. Peter J. Parker, CRUK, London Research Institute, London, UK
    PKC epsilon controls the final committed step in cell division
  • 16.00 - 16.40:
  •   Dr. Jürgen Wagner, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Protein kinase C inhibition: a novel approach to prevent solid organ rejection
  • 16.40 - 17.10:
  •   Coffee
  • Session XII
  •   Chair: Prof. Kurt Ballmer-Hofer, Paul Scherrer Institute, Villigen, Switzerland
  • 17.10 - 17.50:
  •   Dr. Sandra Jacob, Novartis Institutes for Biomedical Research, Basel, Switzerland
    Structural biology contributions to tyrosine kinase drug discovery projects
  • 17.50 - 18.30:
  •   Dr. Pascal Furet, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Protein kinase inhibitors by design
  • 18.30 - 19.10:
  •   Dr. Doriano Fabbro, Novartis Institutes for Biomedical Research, Basel, Switzerland
    Multitargeted kinase inhibitors: an old concept with a new name?
  • 19.10
  •   Closing Party